Please check your internet connection and try again.
# **Omvalixipag-dsty (Durveqix)** Gene Therapy
## Overview
Omvalixipag-dsty is a one-time gene therapy indicated for the treatment of children aged 12 months and older with genetically confirmed **biallelic mutations** causing **Glycogen Storage Disease Type Ia (GSD Ia)**. It aims to introduce a functional copy of the **glucose-6-phosphatase-alpha (G6PC)** gene.
## Primary Indications
* Treatment of GSD Ia in pediatric patients.
## Adult Dosing
* Not applicable. The drug is indicated only for pediatric patients.
## Pediatric Dosing
* **One-time intravenous infusion.**
* The recommended dose is **1.5 x 10^13 vector genomes per kilogram (vg/kg)**.
* The maximum dose per patient is **1.5 x 10^13 vg/kg**.
* Specific infusion protocols (e.g., duration, pre-medications) are determined by the treating center and should be followed meticulously.
## Dose Adjustments
* No dose adjustments are specified based on renal or hepatic impairment, as it is a one-time gene therapy.
* The dose is weight-based and administered once.
## Contraindications
* None listed. However, caution is advised in patients with hypersensitivity to any component of the formulation, including excipients.
## Adverse Effects
* **Common:** Hepatobiliary disorders (e.g., elevated liver enzymes), thrombocytopenia, gastrointestinal disorders (e.g., vomiting, diarrhea), pyrexia, upper respiratory tract infections, anemia, neutropenia.
* **Serious:** Immune-mediated reactions, including liver injury, can occur. Potential for complement activation and infusion-related reactions. Long-term risk of malignancy due to integration of the vector into the host genome cannot be ruled out.
## Key Drug Interactions
* **Immunosuppressive therapy:** Concomitant use may alter the immune response to the gene therapy. Careful management of immunosuppression is crucial, especially in the initial post-infusion period.
* No other specific drug interactions are identified; however, caution should be exercised with any concomitant medications, particularly those affecting the liver or hematologic system.
## Monitoring
* **Baseline:** Comprehensive liver function tests (ALT, AST, bilirubin), platelet count, complete blood count (CBC) with differential, renal function tests, electrolytes, and G6PC enzyme activity.
* **Post-infusion:**
* **Frequent monitoring of liver function tests, CBC, and platelet counts** for at least 1 year post-infusion.
* Monitoring for signs and symptoms of immune-mediated reactions.
* Monitoring for infusion-related reactions.
* Long-term monitoring for potential adverse events, including malignancies.
* Specific monitoring schedules will be dictated by institutional protocols and the product's prescribing information.
## Clinical Pearls
* This is a **one-time administration** intended to provide a lasting effect.
* Patients must have genetically confirmed biallelic G6PC mutations.
* Management of GSD Ia symptoms (e.g., frequent carbohydrate feeds, monitoring blood glucose) should continue, with adjustments made based on clinical response and post-infusion monitoring.
* Close collaboration between the treating physician, pharmacist, and patient/family is essential for optimal management and monitoring.
* The long-term safety profile is still being established.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always refer to the most current prescribing information and consult with qualified healthcare providers for diagnosis and treatment. The availability and approved uses of medications can vary by region.*
